Florida's Peptide Craze Is Booming — What a New Investigation Found

Peptides are being marketed on TikTok as a shortcut to a younger, sharper-looking face. A pharmaceutical sciences researcher explains why the hype is running well ahead of the evidence, and why sourcing and safety data matter more than ever.

President Trump has picked Dr. Heidi Overton, a physician and White House health policy aide, as his nominee to lead the FDA. If confirmed by the Senate, she would inherit one of the agency's most closely watched open questions: what happens next for peptides like BPC-157 and TB-500 after this summer's advisory panel vote.

Australian doctors are investigating a seventh case of acute liver toxicity linked to black-market peptides sold as retatrutide. Here's what the cluster reveals about counterfeit contamination and why batch-specific testing isn't optional.

A reconstituted FDA advisory panel just overruled its own career scientists to back six peptides for compounding. Here's what actually changed, what didn't, and why verified sourcing still matters most.

Delta sleep-inducing peptide, or DSIP, has become one of the more talked-about compounds in 2026's sleep-and-recovery corner of the peptide world. Interest has outpaced the science, though, and much of what circulates online blurs decades-old animal data with modern marketing claims. Here's a clear look at what DSIP actually is, what the current research does and doesn't support, and why sourcing and purity matter for anyone studying this peptide.

GHK-Cu is a naturally occurring copper-binding tripeptide that has drawn growing interest in dermatology and wound-care research. As demand for peptide-based skin treatments keeps climbing in 2026, it's worth separating what the science actually demonstrates from what's still speculative. Here's a look at what GHK-Cu is, what the current research shows, where the evidence runs out, and why sourcing and purity matter more than ever for anyone studying this compound.

U.S. Customs and Border Protection has flagged a sharp rise in seized peptide shipments moving through international mail facilities and ports of entry in 2026, a trend regulators tie to surging consumer demand for weight-loss and wellness peptides. For the research community, the enforcement data underscores a persistent problem: as demand climbs, so does the incentive to counterfeit. Here's what the seizure trends show, why counterfeits are proliferating, and how legitimate researchers can protect the integrity of their work.

Eli Lilly has filed six lawsuits against wellness and compounding vendors it accuses of selling retatrutide, its unapproved obesity drug candidate, to consumers under the guise of "research use only" peptide sales. Here's what the lawsuits allege and what they signal for the broader research peptide industry.

A major telehealth brand just signaled that peptides are going mainstream. Here's what Hims & Hers' 2026 peptide launch means for the research community and quality-focused buyers.